A. Janmohamed

发表

Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome

E. Shephard, Robert L. Smith, C. Dolphin, 1997, Nature Genetics.

Quantification and cellular localization of expression in human skin of genes encoding flavin-containing monooxygenases and cytochromes P450.

I. Phillips, E. Shephard, C. Dolphin, 2001, Biochemical pharmacology.

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

K. C. Morris, Mohammed Salah Ibrahim, K. Y. Wong, 2022, medRxiv.

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Patricia A. H. Williams, Steve B Jones, K. Y. Wong, 2021, The Lancet.

An unusual cause of lower gastrointestinal haemorrhage

C. Elton, A. Saini, A. Janmohamed, 2011, BMJ Case Reports.

Cell-, tissue-, sex- and developmental stage-specific expression of mouse flavin-containing monooxygenases (Fmos).

I. Phillips, E. Shephard, D. Hernandez, 2004, Biochemical pharmacology.

Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: identification of novel gene and pseudogene clusters.

I. Phillips, E. Shephard, D. Hernandez, 2004, Pharmacogenetics.

Longitudinal comparisons of mental health, burnout and well-being in patient-facing, non-patient-facing healthcare professionals and non-healthcare professionals during the COVID-19 pandemic: findings from the CoPE-HCP study

S. Antoniou, M. Khanji, T. Godec, 2022, BJPsych open.

Challenges in Cardiovascular Pharmacogenomics Implementation: A viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.

B. Lewis, M. Caulfield, M. Pirmohamed, 2021, European heart journal. Cardiovascular pharmacotherapy.

Compound heterozygosity for missense mutations in the flavin-containing monooxygenase 3 (FM03) gene in patients with fish-odour syndrome.

I. Phillips, E. Shephard, C. Dolphin, 2000, Pharmacogenetics.

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Steve B Jones, K. Y. Wong, Chamil H. Hettiarachchi, 2021, Lancet.

The Role of Pharmacogenomics in Contemporary Cardiovascular Therapy: A position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy.

B. Lewis, M. Caulfield, M. Pirmohamed, 2021, European heart journal. Cardiovascular pharmacotherapy.

Functional convergence of signalling by GPI-anchored and anchorless forms of a salamander protein implicated in limb regeneration

P. B. Gates, J. Brockes, A. Garza-Garcia, 2011, Journal of Cell Science.

The Flavin-containing Monooxygenase 2 Gene (FMO2) of Humans, but Not of Other Primates, Encodes a Truncated, Nonfunctional Protein*

I. Phillips, E. Shephard, Robert L. Smith, 1998, The Journal of Biological Chemistry.

A novel mutation in the flavin-containing monooxygenase 3 gene, FM03, that causes fish-odour syndrome: activity of the mutant enzyme assessed by proton NMR spectroscopy.

I. Phillips, R. Chalmers, H. Michelakakis, 2000, Pharmacogenetics.

Organization and evolution of the flavin-containing monooxygenase genes of human and mouse

I. Phillips, E. Shephard, D. Hernandez, 2004 .

Determination of Cellular Localization of Expression of Flavin-Containing Monooxygenase Genes in Mouse Tissues by In Situ Hybridization.

I. Phillips, E. Shephard, A. Janmohamed, 2006, Methods in molecular biology.

Outcomes from treating tuberculosis with rifampicin or rifabutin in HIV-infected persons also receiving antiretroviral therapy.

A. Copas, T. Rawson, A. Pozniak, 2015, Journal of acquired immune deficiency syndromes.

The phenotype of a flavin-containing monooyxgenase knockout mouse implicates the drug-metabolizing enzyme FMO1 as a novel regulator of energy balance.

I. Phillips, E. Shephard, B. Omar, 2014, Biochemical pharmacology.

Deletion of the mouse Fmo1 gene results in enhanced pharmacological behavioural responses to imipramine

I. Phillips, E. Shephard, D. Hernandez, 2009, Pharmacogenetics and genomics.

13th International Symposium on Microsomes and Drug Oxidations

M. Bootman, I. Phillips, E. Shephard, 2000 .

Deletion of the mouse Fmo1 gene results in enhanced pharmacological behavioural responses to imipramine

I. Phillips, E. Shephard, D. Hernandez, 2009, Pharmacogenetics and genomics.

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

K. C. Morris, Michele R. Shaw, Mohammed Salah Ibrahim, 2023, The Lancet.

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

K. Y. Wong, Mohammad A. Qayum, John S. Clouston, 2022, Lancet.

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

K. Y. Wong, Beverley E. Crane, Scott M Elliott, 2021, Lancet.

Deletion of Genes From the Mouse Genome Using Cre/loxP Technology.

I. Phillips, E. Shephard, D. Hernandez, 2006, Methods in molecular biology.

Living with trimethylaminuria and body and breath malodour: personal perspectives

E. Shephard, A. Janmohamed, Ian R. Phillips, 2024, BMC public health.

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Patricia A. H. Williams, K. Y. Wong, Ayesha Binte Ashfaq, 2021, Lancet.

Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications.

R. Wilensky, J. Stehli, K. Kario, 2023, Journal of the American College of Cardiology.